metastatic pancreatic ductal adenocarcinoma DrugCendR
DrugCendR begins CEND1-001 trial for pancreatic cancer
DrugCendR has started the Phase l CEND1-001 trial to examine the safety, tolerability, and biologic activity of CEND-1 in combination…
DrugCendR has started the Phase l CEND1-001 trial to examine the safety, tolerability, and biologic activity of CEND-1 in combination…